Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Prolia® and Xgeva® (denosumab) are indicated for the treatment of bone disease, with combined sales of nearly US$5.3 billion in 2021AVT03 (denosumab) is the 4th product in Alvotech’s portfolio to...
-
Prolia® og Xgeva® (denosumab) eru lyf við sjúkdómum í beinum og námu tekjur af sölu þeirra um 730 milljörðum króna á síðasta áriAVT03 (denosumab) er fjórða líftæknilyfjahliðstæða Alvotech sem tekin er...
-
Prolia® and Xgeva® (denosumab) are indicated for the treatment of bone disease, with combined sales of nearly US$5.3 billion in 2021 AVT03 (denosumab) is the 4th product in Alvotech’s portfolio to...
-
Fjölbreyttari samsetning stjórnar með aðkomu óháðra stjórnarmanna Alvotech (NASDAQ og First North Growth „ALVO“) tilkynnti í dag um fjölgun í stjórn fyrirtækisins, í tengslum við skráningu...
-
Four new members enhance independence and diversity of Board of Directors Alvotech (NASDAQ and First North Growth Market: ALVO), a global biotech company specialized in the development and...
-
Four new members enhance independence and diversity of Board of DirectorsAlvotech is dual listed on NASDAQ in the U.S. and NASDAQ First North Growth Market in Iceland under the symbol “ALVO” ...
-
AVT06 er þriðja líftæknilyfjahliðstæða Alvotech sem tekin er til klínískrar rannsóknarGert er ráð fyrir að um 444 sjúklingar taki þátt í rannsókninni Eylea® (aflibercept) er lyf við augnsjúkdómum en...
-
AVT06 is the third biosimilar candidate developed by Alvotech to enter clinical studiesEylea® (aflibercept) is used for the treatment of eye disorders and reached global sales of nearly US$10 billion...
-
AVT06 is the third biosimilar candidate developed by Alvotech to enter clinical studies Eylea® (aflibercept) is used for the treatment of eye disorders and reached global sales of nearly US$10...
-
The board of directors of Alvotech (the “Company”) has resolved to increase the Company´s share capital by an amount of two hundred seventy thousand seven hundred twenty-one US dollars and sixty-seven...